Agile Therapeutics Revenue, Profits - AGRX Annual Income Statement

Add to My Stocks
$0.58 $0.01 (1.75%) AGRX stock closing price Jun 19, 2018 (Closing)

Looking at financial statements, along with the Agile Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement for AGRX which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Revenue for year 2017 is $- and has decreased from $- year on year as is evident when you compare the latest figures in the latest Agile Therapeutics profit and loss statement with those of the prior corresponding period. Also see Agile Therapeutics assets and Agile Therapeutics free cash flow for a complete valuation of AGRX stock.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Agile Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)------
Agile Therapeutics Gross Profit
Research & Development Expense14.42M20.92M25.62M13.36M9.15M17.38M
Selling General & Admin Expense12.38M8.79M7.46M5.15M3.57M5.92M
Income Before Depreciation Depletion Amortization-26.81M-29.72M-33.08M-18.51M-12.72M-23.31M
Depreciation Depletion Amortization------
Non Operating Income---1.14M--0.07M-
Interest Expense1.91M2.44M2.07M1.56M1.51M-
Agile Therapeutics Pretax Income
Provision for Income Taxes--3.07M-5.97M-3.65M--
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-28.3M-28.74M-30.33M-16.07M-14.32M-23.26M
Extraordinary Items & Discontinued Operations------
Agile Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS30.94M28.27M22.02M11.4M8.99M-
Average Shares used to compute Basic EPS30.94M28.27M22.02M11.4M8.99M-
Income Before Nonrecurring Items-28.3M-31.82M-30.34M-16.08M-14.32M-
Income from Nonrecurring Items-3.08M----
Agile Therapeutics Earnings Per Share Basic Net
Agile Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.91-1.13-1.38-1.41-1.59-
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Agile Therapeutics stock analysis. An investor must check the following items in an income statement:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that AGRX stock has a topline or revenue of $- for 2017 as per this Agile Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: Most businesses like Agile Therapeutics try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The AGRX financials along with Agile Therapeutics historical stock prices provide a lot of details about the firm.

Agile Therapeutics Income Statement - Key Financial Ratios